why choose us

First received: October 07, 2024

Clinical Trial: Cystatin C: a Biomarker of AKI in Aneurysmal Subarachnoid Haemorrhage Patients

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Acute Kidney Injury

Study Type: OBSERVATIONAL


Official Title: Cystatin C As a Predictive Biomarker of Acute Kidney Injury and Neurological Outcomes in Aneurysmal Subarachnoid Haemorrhage Patients

Brief Summary: The goal of this observational study is to assess cystatin c as a predictive biomarker of early acute kidney injury in aneurysmal subarachnoid hemorrhage patients.The main question it aims to answer is:- Does cystatin c biomarker can predict early acute kidney injury in aneurysmal subarachnoid hemorrhage patients?Participants will be grouped into Aki and Non-Aki groups based on RIFLE criteria and Cystatin c biomarker will be tested to answer the study question.

Read more